Indicación del tratamiento con doble antiagregación más allá del año. A quién y por qué

Abstract

Currently, dual antiplatelet therapy with acetylsalicylic acid and an ADP-P2Y12 receptor inhibitor is regarded as the treatment of choice for patients with acute coronary syndrome and for those who have undergone percutaneous coronary intervention with coronary stent implantation. Clinical practice guidelines recommend that dual antiplatelet therapy is maintained for 12 months in most contexts and prolonging therapy beyond this time remains controversial. The aim of this article was to present a review of the literature available on which patients would benefit from the prolongation of dual antiplatelet therapy.